Remepy
PrivateLast Round
Series A
Aug 12, 2026
Total Funding Raised
$51M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Remepy operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in August 2026.
Remepy is a biotechnology company that develops hybrid drugs, which combine traditional medications with digital therapeutic software to enhance treatment effectiveness.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical AI, Patient Engagement
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remepy Comparables
Compare Remepy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amalgam Rx | 78% | |
| Click Therapeutics | 78% | |
| Newel Health | 74% |
For institutional investors. Book with your work email.
Remepy Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 12, 2026 | ||||
| Seed | May 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Remepy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vine Ventures | Series A, Seed |
| NFX | Series A, Seed |
| Fresh.Fund | Pre Seed, Series A, Seed |
| Firstime | Seed |
| IT-Farm Corporation | Series A |
| StageNext Fund | Pre Seed, Seed |
| Qumra Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 64% MoM, reaching 6.2K.
- Aug 12, 2026
$36M round led by M Ventures and O.G. Venture Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardNov 2, 2026
At the Tech1 Gala and Awards night, Remepy, Inc. Co-Founder and Co-CEO Michal Tsur receives the CEO of the Year award.
- attends_eventNov 2, 2026
Remepy, Inc. attends the Tech1 Gala and Awards night, where Co-Founder and Co-CEO Michal Tsur receives the CEO of the Year award.
- is_developingSep 16, 2026
Remepy, Inc. is developing Hybrid Drugs that combine prescription medicines with personalized, AI-driven therapeutic apps; its Hybridopa program shows encouraging Phase IIa results, and global Phase III development is expected to commence in Q4 '26.
- hiresSep 16, 2026
Remepy, Inc. appoints Eran Harary, MD, as Chief Medical Officer effective Oct 1st '26 in New York, adding him to its executive management team to advance clinical development, trial execution, and medical and regulatory engagement across its Hybrid Drug pipeline.
- is_developingAug 13, 2026
Remepy, Inc. develops Hybrid Drugs through pharmaceutical partnerships, combining prescription medicines with personalized, AI-driven therapeutic apps and adaptive physical, cognitive, and behavioral interventions.
For institutional investors. Book with your work email.
Remepy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Remepy's valuation, stock price, and market status.
Is Remepy a public or private company?
Remepy is a private company.
What is the current stock price of Remepy?
Remepy is a private company, so its shares have no public market price. Caplight tracks Remepy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Remepy worth (valuation)?
Valuation information for Remepy is not publicly available.
Can I buy Remepy stock?
Remepy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Remepy's last funding round?
Remepy's most recent funding round was Series A on August 12, 2026.
Who are the main investors in Remepy?
Key investors in Remepy include NFX, TechAviv, M Ventures, O.G. Venture Partners.
Will Remepy IPO soon?
No public IPO plans have been announced for Remepy.
How can I track Remepy secondary market activity?
Caplight tracks bids, offers, and trades in Remepy's shares on secondary markets.